TrialBMC cancer2019

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.

Lee Schwartzberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.